MedTrace Logo

Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study

NCT05556291 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 190

Last updated 2025-03-20

No results posted yet for this study

Summary

Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study to evaluate the efficacy, safety and tolerability of Ertugliflozin and Sitagliptin Con-initiation in patients with Type II Diabetes Mellitus in the Pakistani population. The study duration will be 12 months.

Conditions

  • Efficacy
  • Safety
  • Tolerability

Interventions

DRUG

Combinations of Oral Blood Glucose Lowering Drugs

Combination of Ertugliflozin and Sitagliptin

Sponsors & Collaborators

  • Primary Care Diabetes Association, Pakistan

    collaborator OTHER

  • Getz Pharma

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-07-01
Completion
2024-12-01
FDA Drug
Yes

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05556291 on ClinicalTrials.gov